活性药物成分市场－全球产业规模、份额、趋势、机会和预测（按合成类型、应用、地区和竞争细分，2020-2030 年）

2024年，全球活性药物成分 (API) 市值为1,554.1亿美元，预计2030年将达到2,276.7亿美元，预测期内复合年增长率为6.77%。随着製药公司不断拓展其治疗产品组合，以应对包括肿瘤、心血管疾病、神经系统疾病、糖尿病和呼吸系统疾病在内的一系列疾病，对API的需求正在稳步增长。这种激增主要是由于全球慢性病负担日益加重、人口老化以及生活方式的改变。

市场格局正受到日益严格的监管审查的影响，监管重点集中在良好生产规范 (GMP) 和严格的品质控制标准。 API 製造商正透过投资先进技术、改进流程自动化和优先考虑环境永续性来应对这项挑战。随着全球供应链的不断多元化，对于寻求保持竞争力并满足製药业动态需求的製造商而言，在法规合规性、基础设施和地理适应性方面的策略性投资仍将至关重要。

关键市场驱动因素

医疗保健产业的成长

主要市场挑战

生产成本高

主要市场趋势

胜肽和寡核苷酸 API 的兴起

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：COVID-19 对全球活性药物成分市场的影响

第五章：全球活性药物成分市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依合成类型（生物技术、发酵、植物萃取、合成）
  • 按应用（心血管疾病、肿瘤学、神经系统疾病、骨科疾病、呼吸系统疾病、胃肠道疾病、泌尿科、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美活性药物成分市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第七章：欧洲活性药物成分市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区活性药物成分市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第九章：南美活性药物成分市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东和非洲活性药物成分市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如有）
• 最新动态

第十三章：干扰：衝突、流行病与贸易壁垒

第 14 章：全球活性药物成分市场：SWOT 分析

第 15 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 16 章：竞争格局

• Teva Pharmaceutical Industries Ltd.
• Bristol-Myers Squibb Company
• Boehringer Ingelheim GmbH
• Merck & Co., Inc.
• GlaxoSmithKline Plc
• Novartis International AG
• F. Hoffmann-La Roche AG
• Sanofi SA
• Eli Lilly and Company
• AbbVie Inc

第 17 章：策略建议

第18章调查会社について・免责事项

The Global Active Pharmaceutical Ingredient (API) Market was valued at USD 155.41 Billion in 2024 and is projected to reach USD 227.67 Billion by 2030, growing at a CAGR of 6.77% during the forecast period. Demand for APIs is rising steadily as pharmaceutical companies broaden their therapeutic portfolios to address a wide array of conditions including oncology, cardiovascular ailments, neurological disorders, diabetes, and respiratory diseases. This surge is largely driven by the growing global burden of chronic illnesses, an aging population, and evolving lifestyle factors.

The market landscape is being shaped by increasing regulatory scrutiny focused on Good Manufacturing Practices (GMP) and stringent quality control standards. API manufacturers are responding by investing in advanced technologies, improving process automation, and prioritizing environmental sustainability. As global supply chains continue to diversify, strategic investment in regulatory compliance, infrastructure, and geographic resilience will remain essential for manufacturers seeking to maintain competitiveness and meet the dynamic needs of the pharmaceutical sector.

Key Market Drivers

Growth in Healthcare Industry

The continued expansion of the global healthcare sector is a primary catalyst for growth in the API market. With healthcare spending exceeding USD 4 trillion annually, pharmaceuticals and biotechnology account for a significant portion-over USD 850 billion-underscoring the vital role APIs play in medical innovation and treatment delivery.

The escalating prevalence of chronic conditions such as cardiovascular diseases, cancer, and diabetes has led to a sharp increase in demand for high-quality, effective APIs. In 2021, noncommunicable diseases (NCDs) accounted for around 43 million deaths worldwide, representing approximately 75% of all non-pandemic-related fatalities. These health burdens drive the need for long-term medication use, prompting pharmaceutical companies to ramp up API production to meet growing therapeutic demands. The development of biologics and high-potency APIs (HPAPIs) further reflects the healthcare sector's focus on targeted, personalized treatments, reinforcing sustained market growth.

Key Market Challenges

High Cost of Production

High production costs present a substantial barrier in the global API market, affecting both manufacturer margins and the affordability of end products. These costs stem from intricate synthesis procedures, rigorous quality and safety requirements, and the rising expense of sourcing raw materials.

Complying with Good Manufacturing Practices (GMP) mandates the use of highly specialized equipment, skilled personnel, and continuous quality assurance efforts, significantly elevating both capital and operational expenditures-particularly in developed markets. Additionally, maintaining consistent output quality, ensuring regulatory compliance, and managing environmentally sustainable operations add further financial strain. This economic burden restricts entry for smaller firms and contributes to price volatility, especially in regions with limited manufacturing infrastructure.

Key Market Trends

Rise of Peptide and Oligonucleotide APIs

A prominent trend shaping the API market is the surge in demand for peptide and oligonucleotide APIs, driven by the global push toward precision medicine and biologically targeted therapies. GLP-1 analogs like semaglutide and liraglutide are gaining attention in the generics segment, particularly for their effectiveness in treating diabetes and obesity.

Peptides, with their high specificity and minimal toxicity, are increasingly used in treating cancers and metabolic or rare genetic disorders. Likewise, oligonucleotide APIs, composed of DNA or RNA sequences, allow for therapeutic targeting at the genetic level, opening new treatment avenues for diseases previously considered intractable. These innovations support the pharmaceutical industry's pivot to high-efficacy treatments, marking a shift from conventional small-molecule drugs to advanced, biologically complex APIs.

Key Market Players

• Teva Pharmaceutical Industries Ltd.
• Bristol-Myers Squibb Company
• Boehringer Ingelheim GmbH
• Merck & Co., Inc.
• GlaxoSmithKline Plc
• Novartis International AG
• F. Hoffmann-La Roche AG
• Sanofi S.A.
• Eli Lilly and Company
• AbbVie Inc

Report Scope

In this report, the Global Active Pharmaceutical Ingredient Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Active Pharmaceutical Ingredient Market, By Type of Synthesis:

• Biotech
• Fermentation
• Plant Extracts
• Synthetic

Active Pharmaceutical Ingredient Market, By Application:

• Cardiovascular Disease
• Oncology
• Neurological Disorders
• Orthopedic Disorders
• Respiratory
• Gastrointestinal Disorders
• Urology
• Others

Active Pharmaceutical Ingredient Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Active Pharmaceutical Ingredient Market.

Available Customizations

Global Active Pharmaceutical Ingredient Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Active Pharmaceutical Ingredient Market

5. Global Active Pharmaceutical Ingredient Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type of Synthesis (Biotech, Fermentation, Plant Extracts, Synthetic)
  • 5.2.2. By Application (Cardiovascular Disease, Oncology, Neurological Disorders, Orthopedic Disorders, Respiratory, Gastrointestinal Disorders, Urology, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Active Pharmaceutical Ingredient Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type of Synthesis
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Active Pharmaceutical Ingredient Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type of Synthesis
      • 6.3.1.2.2. By Application
  • 6.3.2. Mexico Active Pharmaceutical Ingredient Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type of Synthesis
      • 6.3.2.2.2. By Application
  • 6.3.3. Canada Active Pharmaceutical Ingredient Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type of Synthesis
      • 6.3.3.2.2. By Application

7. Europe Active Pharmaceutical Ingredient Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type of Synthesis
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Active Pharmaceutical Ingredient Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type of Synthesis
      • 7.3.1.2.2. By Application
  • 7.3.2. Germany Active Pharmaceutical Ingredient Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type of Synthesis
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Active Pharmaceutical Ingredient Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type of Synthesis
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Active Pharmaceutical Ingredient Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type of Synthesis
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Active Pharmaceutical Ingredient Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type of Synthesis
      • 7.3.5.2.2. By Application

8. Asia Pacific Active Pharmaceutical Ingredient Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type of Synthesis
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Active Pharmaceutical Ingredient Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type of Synthesis
      • 8.3.1.2.2. By Application
  • 8.3.2. India Active Pharmaceutical Ingredient Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type of Synthesis
      • 8.3.2.2.2. By Application
  • 8.3.3. South Korea Active Pharmaceutical Ingredient Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type of Synthesis
      • 8.3.3.2.2. By Application
  • 8.3.4. Japan Active Pharmaceutical Ingredient Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type of Synthesis
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Active Pharmaceutical Ingredient Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type of Synthesis
      • 8.3.5.2.2. By Application

9. South America Active Pharmaceutical Ingredient Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type of Synthesis
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Active Pharmaceutical Ingredient Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type of Synthesis
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Active Pharmaceutical Ingredient Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type of Synthesis
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Active Pharmaceutical Ingredient Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type of Synthesis
      • 9.3.3.2.2. By Application

10. Middle East and Africa Active Pharmaceutical Ingredient Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type of Synthesis
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Active Pharmaceutical Ingredient Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type of Synthesis
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Active Pharmaceutical Ingredient Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type of Synthesis
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Active Pharmaceutical Ingredient Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type of Synthesis
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Active Pharmaceutical Ingredient Market: SWOT Analysis

15. Porters Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Products

16. Competitive Landscape

• 16.1. Teva Pharmaceutical Industries Ltd.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. Bristol-Myers Squibb Company
• 16.3. Boehringer Ingelheim GmbH
• 16.4. Merck & Co., Inc.
• 16.5. GlaxoSmithKline Plc
• 16.6. Novartis International AG
• 16.7. F. Hoffmann-La Roche AG
• 16.8. Sanofi S.A.
• 16.9. Eli Lilly and Company
• 16.10. AbbVie Inc

17. Strategic Recommendations

18. About Us & Disclaimer